Suppr超能文献

哮喘缓解期患者气道阻塞和高反应性的持续存在。

Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission.

作者信息

Boulet L P, Turcotte H, Brochu A

机构信息

Unité de Recherche, Hôpital Laval, Université Laval, Sainte-Foy, Canada.

出版信息

Chest. 1994 Apr;105(4):1024-31. doi: 10.1378/chest.105.4.1024.

Abstract

This study was designed to determine if there is residual airflow obstruction and/or airway hyperresponsiveness in adults with symptomatic asthma remission, and if age at remission or its duration influence these parameters. We studied 30 subjects, (20 men, 10 women, 28 atopics, aged 18 to 61 years; mean, 32 years) with a history of asthma (mean duration, 2 to 33 years) but who reported no symptoms or medication requirement for > or 2 years. They were individually matched for age, sex, and atopy, to a control group of 30 subjects without history of asthma. Each subject had a respiratory questionnaire and measurements of expiratory flows, lung volumes, and bronchodilator response. Morning/evening peak expiratory flow rates (PEFRs) were recorded for a 2-week period and two methacholine inhalation tests were obtained on separate days. Initial FEV1 and FVC for ex-asthmatics (controls) were, respectively, 91.0 +/- 2.5 percent and 97.8 +/- 2.3 percent (104.1 +/- 1.9 and 104.0 +/- 1.8 percent) of predicted values. Twenty nine ex-asthmatics (15 controls) had occasional respiratory symptoms, not attributed to asthma. Most subjects with asthma remission had evidences of mild airflow obstruction, associated to a methacholine response either increased in 11 (PC20 methacholine, 0.18 to 5.6 mg/ml) or "borderline" in 10 others (PC20 between 8 and 20 mg/ml). Airway responsiveness was normal (PC20 > 20 mg/ml) in 8 ex-asthmatics and in 21 controls (PC20 was under 8 mg/ml and between 10 and 20 mg/ml in, respectively, 5 and 4 controls). Mean reversibility of FEV1 after 200 micrograms of albuterol was 5.7 (range, -1.1 to 14.1 percent) compared with 2.5 (-4.4 to 10.5) in controls. Mean and maximal diurnal variation of PEFR were, respectively, 4.6 +/- 0.4 percent and 12.3 +/- 1.3 percent (controls, 2.9 +/- 0.3 and 7.0 +/- 0.8 percent). There was a significant correlation between PC20 and age at the diagnosis of asthma or at the onset of remission. Airway responsiveness was significantly less when asthma or remission of asthma occurred at a younger age, although there was no difference for baseline FEV1 and no significant correlation between PC20 and duration of asthma or of remission. Perception of bronchoconstriction was similar in both controls and ex-asthmatics. In conclusion, most ex-asthmatics who considered to be in asthma remission showed a persistent increase in airway responsiveness with or without mild airflow obstruction, suggesting that symptom report may be insufficient to determine that asthma is in true remission.

摘要

本研究旨在确定症状性哮喘缓解期的成年人是否存在残余气流阻塞和/或气道高反应性,以及缓解期的年龄或其持续时间是否会影响这些参数。我们研究了30名受试者(20名男性,10名女性,28名特应性体质者,年龄在18至61岁之间;平均32岁),他们有哮喘病史(平均病程2至33年),但报告>2年无症状或无需药物治疗。他们在年龄、性别和特应性体质方面与30名无哮喘病史的对照组受试者进行个体匹配。每位受试者都进行了呼吸问卷调查,并测量了呼气流量、肺容积和支气管扩张剂反应。记录了2周的早晚呼气峰值流速(PEFR),并在不同日期进行了两次乙酰甲胆碱吸入试验。哮喘缓解者(对照组)的初始第一秒用力呼气容积(FEV1)和用力肺活量(FVC)分别为预测值的91.0±2.5%和97.8±2.3%(104.1±1.9和104.0±1.8%)。29名哮喘缓解者(15名对照组)偶尔有呼吸道症状,但并非由哮喘引起。大多数哮喘缓解的受试者有轻度气流阻塞的证据,其中11名受试者的乙酰甲胆碱反应增加(乙酰甲胆碱激发试验PC20为0.18至5.6mg/ml),另外10名受试者的反应为“临界”(PC20在8至20mg/ml之间)。8名哮喘缓解者和21名对照组受试者的气道反应性正常(PC20>20mg/ml)(分别有5名和4名对照组受试者的PC20低于8mg/ml和在10至20mg/ml之间)。与对照组相比,200微克沙丁胺醇后FEV1的平均可逆性为5.7(范围为-1.1至14.1%),而对照组为2.5(-4.4至10.5)。PEFR的平均和最大日变化分别为4.6±0.4%和12.3±1.3%(对照组为2.9±0.3和7.0±0.8%)。PC20与哮喘诊断时或缓解开始时的年龄之间存在显著相关性。哮喘或哮喘缓解发生在较年轻时,气道反应性明显较低,尽管基线FEV1无差异,且PC20与哮喘病程或缓解持续时间之间无显著相关性。对照组和哮喘缓解者对支气管收缩的感知相似。总之,大多数被认为处于哮喘缓解期的哮喘缓解者显示气道反应性持续增加,伴有或不伴有轻度气流阻塞,这表明症状报告可能不足以确定哮喘是否真正缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验